Clinical Trial

Immunophotonics to Present at the 2024 ThinkEquity Conference

ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development…

2 months ago

Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease

New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients HOUSTON, TX, Oct. 28, 2024 (GLOBE…

2 months ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct.…

2 months ago

Therma Bright’s Investment Partnership InStatin Joins Forces with InVixa to Enhance Its Patent Portfolio For The Development Of Innovative Respiratory Solutions

InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung diseaseToronto, Ontario--(Newsfile…

2 months ago

CluePoints Appoints Richard Young as Chief Strategy Officer

KING OF PRUSSIA, Pa., Oct. 28, 2024 /PRNewswire/ -- RBQM innovator CluePoints has today announced that Richard Young has been…

2 months ago

3Aware and RQM+ Forge Partnership to Enhance MedTech Compliance and Innovation

INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical…

2 months ago

AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

2 months ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after…

3 months ago

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…

3 months ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients…

3 months ago